Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Solid Cancers: early-phase trial registry
1 of 2 indexed Advanced Solid Cancers trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Advanced Solid Cancers: 2 US clinical trials tracked, 1 recruiting.
Advanced Solid Cancers is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is BioNTech SE, running 1 of these trials.
Enrollment posture brief
Registry condition advanced-solid-cancers
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Advanced Solid Cancers lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Solid Cancers on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Solid Cancers is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
NCT07186842
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
Bristol-Myers Squibb
NCT03956680
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Solid Cancers records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Solid Cancers trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Solid Cancers page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Advanced Solid Cancers trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- BioNTech SE sponsors the most Advanced Solid Cancers trials on record, review their full trial history before evaluating a specific study. See BioNTech SE's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Solid Cancers condition card totals 2 registered trials; most-linked intervention BMS-986301; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.